Imunon, Inc. (IMNN) Latest Company News

Sep 29, 2026, 12:03 UTC
Imunon, Inc. exchanged $1.2 million of its Secured Promissory Note A-1 for 120 shares of Series B Preferred Stock at $10,000 per share with Streeterville Capital, LLC.
Source:
- globenewswire.com
Sep 22, 2026, 12:05 UTC
IMUNON announced that an Independent Data Monitoring Committee recommended continuing Phase 2 development of IMNN-001 without modification following a favorable safety review of the ongoing MRD study.
Source:
- globenewswire.com
Sep 10, 2026, 13:30 UTC
Imunon entered a Cooperative Research and Development Agreement with the National Cancer Institute's Cancer Therapy Evaluation Program to advance clinical development of IMNN-001 in new indications and combination regimens.
Source:
- globenewswire.com
Aug 11, 2026, 00:00 UTC
Imunon, Inc. reported a net loss of $2.8 million for Q2 2026, with a diluted loss per share of $0.54, and provided updates on its clinical studies including OVATION 2 and OVATION 3 trials for IMNN-001.
Source:
- seekingalpha.com
Jun 23, 2026, 12:00 UTC
IMUNON announced that the independent Data Monitoring Committee recommended continuation of the Phase 3 OVATION 3 study without modification.
Source:
- globenewswire.com
Jun 16, 2026, 00:00 UTC
Imunon, Inc. elected Christine A. Pellizzari as a Class I director of its board of directors, effective June 16, 2026.
Jun 16, 2026, 00:00 UTC
Imunon, Inc. elected Frederick J. Fritz as a Class I director of its board of directors, effective June 16, 2026.
Jun 4, 2026, 00:00 UTC
Imunon, Inc. issued $7.72 million aggregate principal amount of secured promissory notes (8% A-1 Note and 5% B Note) due 2027, with proceeds for general corporate purposes.
Source:
- globenewswire.com

IMNN

Imunon, Inc. exchanged $1.2 million of its Secured Promissory Note A-1 for 120 shares of Series B Preferred Stock at $10,000 per share with Streeterville Capital, LLC.

IMUNON announced that an Independent Data Monitoring Committee recommended continuing Phase 2 development of IMNN-001 without modification following a favorable safety review of the ongoing MRD study.

Imunon entered a Cooperative Research and Development Agreement with the National Cancer Institute's Cancer Therapy Evaluation Program to advance clinical development of IMNN-001 in new indications and combination regimens.

Imunon, Inc. reported a net loss of $2.8 million for Q2 2026, with a diluted loss per share of $0.54, and provided updates on its clinical studies including OVATION 2 and OVATION 3 trials for IMNN-001.

IMUNON announced that the independent Data Monitoring Committee recommended continuation of the Phase 3 OVATION 3 study without modification.

Imunon, Inc. elected Christine A. Pellizzari as a Class I director of its board of directors, effective June 16, 2026.

Imunon, Inc. elected Frederick J. Fritz as a Class I director of its board of directors, effective June 16, 2026.

Imunon, Inc. issued $7.72 million aggregate principal amount of secured promissory notes (8% A-1 Note and 5% B Note) due 2027, with proceeds for general corporate purposes.